Chemical formula: C₁₅H₁₂N₂O₂ Molecular mass: 252.268 g/mol PubChem compound: 34312
The pharmacological activity of oxcarbazepine is primarily exerted through the metabolite (MHD). The mechanism of action of oxcarbazepine and MHD is thought to be mainly based on the blockade of voltage-sensitive sodium channels.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| N03AF02 | Oxcarbazepine | N Nervous system → N03 Antiepileptics → N03A Antiepileptics → N03AF Carboxamide derivatives |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| OXCARBAZEPINE MYLAN Film-coated tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Oxcarbazepine is an active ingredient of these brands:
United States (US)Australia (AU)Austria (AT)Canada (CA)Croatia (HR)Cyprus (CY)France (FR)Ireland (IE)Israel (IL)Italy (IT)Lithuania (LT)Mexico (MX)Netherlands (NL)New Zealand (NZ)Romania (RO)South Africa (ZA)Spain (ES)United Kingdom (UK)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
